Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Accelerates: Strategic Forecast Predicts $17.25 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Market Size Be by 2025?
The market size for treatments concerning attention deficit hyperactivity disorder (ADHD) has seen an impressive growth in the past few years. It is predicted to rise from the 2024 valuation of $13.21 billion to an estimated $14.1 billion by 2025, showcasing a compound annual growth rate (CAGR) of 6.7%. This substantial growth during the historic period is the result of increased awareness and implementation of diagnostic and screening programs, a spike in ADHD cases, the evolution of treatment approaches, advancements in healthcare infrastructure, and extended health insurance coverage.

What's the Long-Term Growth Forecast for the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Through 2029?
Growth is anticipated in the therapeutics market for attention deficit hyperactivity disorder (ADHD), with the market size projected to reach $17.25 billion in 2029, reflecting a compound annual growth rate (CAGR) of 5.2%. This growth over the forecast period can be associated with factors such as genetic research and individualized treatments, increased awareness about mental health, international and national mental health campaigns, telehealth proliferation, and integration of behavioural therapies. Key trends within the forecast period encompass technological advancements in treatment, research, and development efforts, incorporation of digital therapeutics, precision medicine methodologies, and breakthroughs in drug delivery systems.

View the full report here:
https://www.thebusinessresearchcompany.com/report/attention-deficit-hyperactivity-disorder-adhd-therapeutics-global-market-report

What Are the Key Growth Drivers Fueling the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Expansion?
The escalating rates of attention-deficit hyperactivity disorder are projected to stimulate the expansion of the ADHD therapeutics market. The term refers to the increasing number of individuals diagnosed with this neurodevelopmental disorder. ADHD therapies target the complex nature of the disorder and strive to enhance symptom control, minimize functional disturbances, improve quality of life, and boost overall well-being of those impacted. For instance, per The Guardian's reports in January 2023, a US-based publishing company, the number of patients prescribed for ADHD rose to an estimated 170,000 in 2022, showing a 20.4% growth from 141,000 patients diagnosed during the same timeframe in 2021. Thus, the upward trend in ADHD prevalence is fueling the expansion of the ADHD therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp

What Are the Key Trends Driving Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth?
Major players in the ADHD therapeutics market are prioritizing the creation of digital advancements such as Endeavor OTC versions of digital therapies for ADHD, in response to the growing demand for digital solutions and remote healthcare. Functioning as evidence-supported treatment interventions, digital therapeutics utilize high-quality software to prevent, manage, or treat medical disorders or diseases. These interventions are made with the intention of being used independently or in conjunction with traditional medical treatments. For example, in June 2023, Akili, a digital health firm based in the US, introduced an OTC edition of its video game-based digital therapy for adults with ADHD. The OTC variant, named EndeavorOTC, aims to enhance attention, time management and organizational skills. This initiative is built upon the success of Akili's FDA-approved prescription video game treatment, EndeavorRx, for children with ADHD. The OTC version grants adults a non-medicinal treatment Alternative for handling their ADHD symptoms.

How Is the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segmented?
The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented -

1) By Drug Type: Stimulants, Non-Stimulants
2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy
3) By Age Group: Pediatric And Adolescent, Adult
4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce

Subsegments:
1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants
2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp

Which Companies Are Leading the Charge in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Innovation?
Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical's, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.

Which Regions Are Leading the Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market in Revenue?
North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14042

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.